Duration of immunity to experimental infection with bovine respiratory syncytial virus following intranasal vaccination of young passively immune calves

Ellis, John; Gow, Sheryl; Mahan, Suman M.; Leyh, Randy D.

doi:10.2460/javma.243.11.1602

Cited by 39 publications

(46 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although not evaluated herein, the duration of protection might be limited after a single mucosal administration [64], and theoretically, a homologous mucosal boost of ΔSHrBRSV might be ineffective, due to vaccine neutralization by secretory IgA antibodies. Boosting intramuscularly with ΔSHrBRSV or SUMont could thus prolong and potentiate protective immunity, by activating several arms of the immune system.…”

Section: Discussionmentioning

confidence: 99%

Vaccine Safety and Efficacy Evaluation of a Recombinant Bovine Respiratory Syncytial Virus (BRSV) with Deletion of the SH Gene and Subunit Vaccines Based On Recombinant Human RSV Proteins: N-nanorings, P and M2-1, in Calves with Maternal Antibodies

et al. 2014

View full text Add to dashboard Cite

The development of safe and effective vaccines against both bovine and human respiratory syncytial viruses (BRSV, HRSV) to be used in the presence of RSV-specific maternally-derived antibodies (MDA) remains a high priority in human and veterinary medicine. Herein, we present safety and efficacy results from a virulent BRSV challenge of calves with MDA, which were immunized with one of three vaccine candidates that allow serological differentiation of infected from vaccinated animals (DIVA): an SH gene-deleted recombinant BRSV (ΔSHrBRSV), and two subunit (SU) formulations based on HRSV-P, -M2-1, and -N recombinant proteins displaying BRSV-F and -G epitopes, adjuvanted by either oil emulsion (Montanide ISA71VG, SUMont) or immunostimulating complex matrices (AbISCO-300, SUAbis). Whereas all control animals developed severe respiratory disease and shed high levels of virus following BRSV challenge, ΔSHrBRSV-immunized calves demonstrated almost complete clinical and virological protection five weeks after a single intranasal vaccination. Although mucosal vaccination with ΔSHrBRSV failed to induce a detectable immunological response, there was a rapid and strong anamnestic mucosal BRSV-specific IgA, virus neutralizing antibody and local T cell response following challenge with virulent BRSV. Calves immunized twice intramuscularly, three weeks apart with SUMont were also well protected two weeks after boost. The protection was not as pronounced as that in ΔSHrBRSV-immunized animals, but superior to those immunized twice subcutaneously three weeks apart with SUAbis. Antibody responses induced by the subunit vaccines were non-neutralizing and not directed against BRSV F or G proteins. When formulated as SUMont but not as SUAbis, the HRSV N, P and M2-1 proteins induced strong systemic cross-protective cell-mediated immune responses detectable already after priming. ΔSHrBRSV and SUMont are two promising DIVA-compatible vaccines, apparently inducing protection by different immune responses that were influenced by vaccine-composition, immunization route and regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Vaccine Safety and Efficacy Evaluation of a Recombinant Bovine Respiratory Syncytial Virus (BRSV) with Deletion of the SH Gene and Subunit Vaccines Based On Recombinant Human RSV Proteins: N-nanorings, P and M2-1, in Calves with Maternal Antibodies

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A baixa soroconversão para BRSV pode justificar a detecção de infecção precoce no bezerro 1 (NVAC) entre 15 e 30 dias de vida e no bezerro 10 (VAC) entre oito e 10 dias de vida (Martin e Bohac, 1986). Este achado, associado à baixa transferência de ACs das mães aos recém-nascidos, sinaliza para a adoção de protocolos precoces de vacinação para o BRSV, porém as vacinas para o BRSV tendem a ser de curta duração (<4 meses) (Ellis et al, 2013). As vacinas intranasais compostas por cepas vivas podem ser uma boa estratégia para estimular resposta imune de mucosas sem interferência dos anticorpos maternos (Endsley et al, 2003).…”

Section: Resultsunclassified

Influência da vacinação materna na transferência de imunidade passiva contra as viroses respiratórias dos bovinos

Baccili

Silva

Baldacim

et al. 2018

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

RESUMOO objetivo deste estudo longitudinal foi avaliar a influência da vacinação materna na transferência de anticorpos (ACs) contra as viroses respiratórias em bezerros. Para tanto, vacas e bezerros foram distribuídos em dois grupos conforme a realização (VAC, n=6) ou não (NVAC, n=4) da vacinação no pré-parto. Amostras sanguíneas foram obtidas após a parição (D0); em seguida, apenas os bezerros foram acompanhados até D180. ACs séricos foram determinados pela vírus-neutralização (VN) contra BVDV, BoHV-1, BRSV e BPI3-V. Vacas VAC apresentaram diferenças para ACs contra BoHV-1 (P=0,01) em D0. As frequências (%) de bezerros soropositivos para BoHV-1 foram maiores em VAC do D2 ao D120; para BRSV em D4, D8, D10 e D150 (P≤0,08); medianas de ACs contra BoHV-1 em VAC do D2 ao D120 (P=0,08). A vacinação das vacas no pré-parto foi fundamental para a transferência e a duração de ACs contra BoHV-1 e BRSV, porém o protocolo adotado não foi eficiente para o aumento de ACs para BVDV e BPI3-V. A eficácia parcial da vacinação materna não inviabiliza a sua recomendação devido à importância do Herpesvírus e do BRSV na DRB, porém estratégias para a melhoria nas respostas imunes contra as demais viroses devem ser estabelecidas. to BRSV D4, D8, D10 and D150 (P≤0.08); higher medians of Abs against Palavras-chave: bovino, colostro, anticorpos maternos ABSTRACT

show abstract

“…Additionally, vaccination lowered the odds ratio for BRD diagnosis at the second clinical examination. The efficacy of intranasal vaccinations has been demonstrated in many experimental challenge studies, but very few clinical field trials are available [19,20,25,26]. Ollivett and others [23] conducted a field trial in three dairy herds, where they intranasally vaccinated young calves for bovine rhinotracheitis, parainfluenza-3 virus and respiratory syncytial virus.…”

Section: Discussionmentioning

confidence: 99%

“…Hill and others [18] showed that 3-8 day old Holstein calves are capable of developing mucosal immune response after intranasal vaccination, even when maternal antibodies are present. Other studies of intranasal vaccinations have also shown promising results in young calves (3-14 days old) vaccinated against common respiratory pathogens [19][20][21]. The short duration of immunity after one dose of intranasal vaccination may set a requirement for subsequent booster vaccines [19,22].…”

Section: Introductionmentioning

confidence: 99%

“…Other studies of intranasal vaccinations have also shown promising results in young calves (3-14 days old) vaccinated against common respiratory pathogens [19][20][21]. The short duration of immunity after one dose of intranasal vaccination may set a requirement for subsequent booster vaccines [19,22]. Even though intranasal vaccinations have not reduced the incidence of BRD in some studies, pathological changes in lungs have been reduced [22,23].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Field trial to evaluate the effect of an intranasal respiratory vaccine protocol on bovine respiratory disease incidence and growth in a commercial calf rearing unit

et al. 2020

View full text Add to dashboard Cite

Background: Bovine respiratory disease (BRD) continues to be great challenge in calf rearing units. The urgent need to decrease the use of antibiotics and increase animal welfare in beef production has forced us to introduce new preventive methods. Vaccinations could contribute to the solution, but the high incidence of BRD already at an early age has made it difficult to introduce suitable vaccination programs. Challenge studies have shown promising results in 3-14 day old calves vaccinated with intranasal BRD vaccine, but very few field trials are available to assess the efficacy of the intranasal vaccines in field conditions. We evaluated the effect of one dose of commercial intranasal vaccination on calf mortality, daily gain, and treatment incidence for BRD in one calf rearing unit. In total, 497 calves (mean age 19 days) were included in our study, 247 of which were vaccinated at the time of arrival to the unit and 250 served as negative controls (unvaccinated). Vaccinated and unvaccinated calves were situated in separate compartments until weaning. Daily gain, treatment incidence, and mortality were recorded until the calves were transported to the finishing unit, which averaged 154.5 days from arrival.Results: Average daily gain over the complete study period was 1151.9 g/day (SD 137.9) for the vaccinated calves and 1139.5 g/day (SD 135.9) for the unvaccinated calves. Intranasal vaccination combined with older arrival age (17 days or older) resulted in a higher daily gain (47.8 g/day) compared with unvaccinated calves (coef. 0.0478, p = 0.003). This association was not recorded in calves that were younger than 17 days upon arrival. Intranasal vaccination was not significantly associated either with mortality (OR 0.976, p = 0.968) or treatment incidence for BRD (OR 1.341, p = 0.120). In total, six vaccinated calves (2.43%) and six unvaccinated calves (2.40%) died during the study period.Conclusions: Vaccinating arriving calves with intranasal vaccine in the calf rearing unit did not decrease the mortality or treatment incidence for BRD, but it significantly improved the weight gain in calves transported to the unit at the age of 17 days or older.

show abstract

Duration of immunity to experimental infection with bovine respiratory syncytial virus following intranasal vaccination of young passively immune calves

Cited by 39 publications

References 28 publications

Vaccine Safety and Efficacy Evaluation of a Recombinant Bovine Respiratory Syncytial Virus (BRSV) with Deletion of the SH Gene and Subunit Vaccines Based On Recombinant Human RSV Proteins: N-nanorings, P and M2-1, in Calves with Maternal Antibodies

Vaccine Safety and Efficacy Evaluation of a Recombinant Bovine Respiratory Syncytial Virus (BRSV) with Deletion of the SH Gene and Subunit Vaccines Based On Recombinant Human RSV Proteins: N-nanorings, P and M2-1, in Calves with Maternal Antibodies

Influência da vacinação materna na transferência de imunidade passiva contra as viroses respiratórias dos bovinos

Field trial to evaluate the effect of an intranasal respiratory vaccine protocol on bovine respiratory disease incidence and growth in a commercial calf rearing unit

Contact Info

Product

Resources

About